BEUDAMED
    FDA Adverse Event Death Summary report: N

    ROTALINK BURR

    MDR report key: 25057739 · Received May 1, 2026

    Report

    Report Number
    2124215-2026-23787
    Event Type
    Death
    Date Received
    May 1, 2026
    Date of Event
    October 1, 2016
    Report Date
    May 1, 2026
    Manufacturer
    BOSTON SCIENTIFIC CORPORATION
    Product Code
    MCX
    UDI-DI
    08714729185857
    PMA / PMN Number
    P900056
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    CH
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    INVESTIGATION RESULTS: DEVICE HISTORY REVIEW: A REVIEW WAS NOT COMPLETED OF THE DEVICE HISTORY RECORDS (DHR) FOR THE DEVICE. THE DHR REVIEW CANNOT BE PERFORMED AS NO BATCH NUMBER WAS REPORTED AND A SHIP HISTORY CANNOT BE PERFORMED SINCE THE UPN WAS NOT REPORTED. DEVICE ANALYSIS FINDINGS: THE DEVICE WAS NOT RETURNED FOR ANALYSIS; THEREFORE, A TECHNICAL ANALYSIS COULD NOT BE PERFORMED. LABELING REVIEW: REVIEW OF THE INSTRUCTIONS FOR USE (IFU) CONFIRMED THERE WAS RELEVANT CONTENT AND SUFFICIENT GUIDANCE WITH RESPECT TO THE CIRCUMSTANCES DESCRIBED WITHIN THIS COMPLAINT. NO UPDATES ARE REQUIRED TO THE IFU AS A RESULT OF THIS EVENT. RISK REVIEW: A RISK REVIEW WAS PERFORMED, AND IT CONFIRMED THAT THE EVENT WAS DEFINED IN THE RISK DOCUMENTATION AND IS RECORDED ACCORDINGLY IN THE PRODUCT RECORD REVIEW (PRR) TABLE. THIS EVENT TYPE HAS BEEN ACCOUNTED FOR DURING PRODUCT RISK ANALYSIS TO SUPPORT ACCEPTABLE RISK BENEFIT FOR THE PRODUCT. INVESTIGATION CONCLUSION: BASED ON A THOROUGH REVIEW OF THE REPORTED COMPLAINT AND THE CORRESPONDING LABELING, THE REPORTED ALLEGATION IS A WELL-KNOWN RISK RELATED TO THE USE OF THE DEVICE OR THE PROCEDURE. THE INVESTIGATION CONCLUSION CODE OF KNOWN INHERENT RISK OF DEVICE WAS SELECTED. B3 DATE OF EVENT: EARLIEST POSSIBLE DATE OF EVENT AS THE PATIENT WERE ADMITTED FOR ELECTIVE PCI OCTOBER 2016 TO JUNE 2023. B2 DATE OF DEATH: EARLIEST POSSIBLE DATE OF DEATH AS THE PATIENT WERE ADMITTED FOR ELECTIVE PCI OCTOBER 2016 TO JUNE 2023. E1 INITIAL REPORTER PHONE: (B)(6).

    Additional Manufacturer Narrative · 0

    B3 DATE OF EVENT: EARLIEST POSSIBLE DATE OF EVENT AS THE PATIENT WERE ADMITTED FOR ELECTIVE PCI OCTOBER 2016 TO JUNE 2023 B2 DATE OF DEATH: EARLIEST POSSIBLE DATE OF DEATH AS THE PATIENT WERE ADMITTED FOR ELECTIVE PCI OCTOBER 2016 TO JUNE 2023 E1 INITIAL REPORTER PHONE: (B)(6). DETAILED PRODUCT INFORMATION WAS NOT PROVIDED TO BSC, BECAUSE THE PRODUCT IS UNKNOWN, WE ARE UNABLE TO PROVIDE THE UNIQUE IDENTIFIER (UDI) # AND OTHER SPECIFIC PRODUCT INFORMATION. WU, X., WU, M., HUANG, H. ET AL. PREDICTIVE VALUE OF THE CHA2DS2 VASC HSF SCORE FOR SLOW FLOW DURING ROTATIONAL ATHERECTOMY IN PATIENTS WITH SEVERE CORONARY ARTERY CALCIFICATION. BMC CARDIOVASC DISORD 25, 469 (2025). HTTPS://DOI.ORG/10.1186/S12872-025-04931-1

    Description of Event or Problem · 0

    IT WAS REPORTED VIA LITERATURE ARTICLE PATIENT DEATH OCCURRED. SLOW FLOW IS A FREQUENT COMPLICATION OF ROTATIONAL ATHERECTOMY (RA) FOR SEVERE CORONARY ARTERY CALCIFICATION (CAC), YET EFFECTIVE PREPROCEDURAL RISK STRATIFICATION TOOLS ARE LACKING. THE CHA2DS2 VASC HSF SCORE INCORPORATES MULTIPLE CARDIOVASCULAR RISK FACTORS AND MAY HELP PREDICT ADVERSE PROCEDURAL OUTCOMES. 256 PATIENTS WERE ANALYZED RETROSPECTIVELY WITH SEVERE CAC UNDERGOING RA. PATIENTS WERE DIVIDED INTO A SLOW FLOW GROUP (THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) 0 TO 2) AND NORMAL FLOW GROUP (TIMI 3) BASED ON POST-RA ANGIOGRAPHIC ASSESSMENT. CLINICAL, PROCEDURAL, AND ANGIOGRAPHIC DATA WERE COMPARED. INDEPENDENT PREDICTORS WERE IDENTIFIED USING MULTIVARIATE LOGISTIC REGRESSION, AND RECEIVER OPERATING CHARACTERISTIC ANALYSIS ASSESSED THE PREDICTIVE PERFORMANCE OF VARIABLES. SLOW FLOW OCCURRED IN 18.8% OF PATIENTS. THE SLOW FLOW GROUP HAD SIGNIFICANTLY HIGHER CHA2DS2 VASC HSF SCORES, LONGER LESION LENGTHS, SMALLER REFERENCE VESSEL DIAMETERS, AND LOWER PREPROCEDURAL SYSTOLIC BLOOD PRESSURE (SBP). MULTIVARIATE ANALYSIS IDENTIFIED ALL FOUR AS INDEPENDENT PREDICTORS. THE CHA2DS2 VASC HSF SCORE ALONE HAD MODERATE PREDICTIVE VALUE (AREA UNDER THE CURVE AUC IS 0.658), WHILE A COMBINED MODEL INCORPORATING THE SCORE WITH LESION LENGTH, REFERENCE DIAMETER, AND SBP ACHIEVED THE HIGHEST ACCURACY AUC IS 0.893. SLOW FLOW WAS ALSO ASSOCIATED WITH A HIGHER IN-HOSPITAL RATE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS. THERE WERE 2 IN-HOSPITAL ALL-CAUSE MORTALITY. THE CHA2DS2 VASC HSF SCORE IS AN INDEPENDENT PREDICTOR OF SLOW FLOW DURING RA AND, WHEN COMBINED WITH ANATOMICAL AND HEMODYNAMIC VARIABLES, MAY ENHANCE RISK STRATIFICATION. THESE FINDINGS SUPPORT ITS USE IN PREPROCEDURAL PLANNING FOR PATIENTS WITH SEVERE CAC.

    Description of Event or Problem · 0

    IT WAS REPORTED VIA LITERATURE ARTICLE PATIENT DEATH OCCURRED. SLOW FLOW IS A FREQUENT COMPLICATION OF ROTATIONAL ATHERECTOMY (RA) FOR SEVERE CORONARY ARTERY CALCIFICATION (CAC), YET EFFECTIVE PREPROCEDURAL RISK STRATIFICATION TOOLS ARE LACKING. THE CHA2DS2 VASC HSF SCORE INCORPORATES MULTIPLE CARDIOVASCULAR RISK FACTORS AND MAY HELP PREDICT ADVERSE PROCEDURAL OUTCOMES. 256 PATIENTS WERE ANALYZED RETROSPECTIVELY WITH SEVERE CAC UNDERGOING RA. PATIENTS WERE DIVIDED INTO A SLOW FLOW GROUP (THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) 0 TO 2) AND NORMAL FLOW GROUP (TIMI 3) BASED ON POST-RA ANGIOGRAPHIC ASSESSMENT. CLINICAL, PROCEDURAL, AND ANGIOGRAPHIC DATA WERE COMPARED. INDEPENDENT PREDICTORS WERE IDENTIFIED USING MULTIVARIATE LOGISTIC REGRESSION, AND RECEIVER OPERATING CHARACTERISTIC ANALYSIS ASSESSED THE PREDICTIVE PERFORMANCE OF VARIABLES. SLOW FLOW OCCURRED IN 18.8% OF PATIENTS. THE SLOW FLOW GROUP HAD SIGNIFICANTLY HIGHER CHA2DS2 VASC HSF SCORES, LONGER LESION LENGTHS, SMALLER REFERENCE VESSEL DIAMETERS, AND LOWER PREPROCEDURAL SYSTOLIC BLOOD PRESSURE (SBP). MULTIVARIATE ANALYSIS IDENTIFIED ALL FOUR AS INDEPENDENT PREDICTORS. THE CHA2DS2 VASC HSF SCORE ALONE HAD MODERATE PREDICTIVE VALUE (AREA UNDER THE CURVE AUC IS 0.658), WHILE A COMBINED MODEL INCORPORATING THE SCORE WITH LESION LENGTH, REFERENCE DIAMETER, AND SBP ACHIEVED THE HIGHEST ACCURACY AUC IS 0.893. SLOW FLOW WAS ALSO ASSOCIATED WITH A HIGHER IN-HOSPITAL RATE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS. THERE WERE 2 IN-HOSPITAL ALL-CAUSE MORTALITY. THE CHA2DS2 VASC HSF SCORE IS AN INDEPENDENT PREDICTOR OF SLOW FLOW DURING RA AND, WHEN COMBINED WITH ANATOMICAL AND HEMODYNAMIC VARIABLES, MAY ENHANCE RISK STRATIFICATION. THESE FINDINGS SUPPORT ITS USE IN PREPROCEDURAL PLANNING FOR PATIENTS WITH SEVERE CAC.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    504736 ROTALINK BURR CATHETER, CORONARY, ATHERECTOMY MCX BOSTON SCIENTIFIC CORPORATION 3320 08714729185857

    Patients

    Seq Age Sex Outcome Treatment
    1